Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend
- PMID: 30963467
- DOI: 10.1007/s40618-019-01044-3
Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend
Abstract
Purpose: This is a longitudinal study of retrospective data aimed at verifying whether repeated measurements of serum non-stimulated thyroglobulin (Tg) allow the prediction of persistent disease in patients with differentiated thyroid cancer (DTC) and indeterminate response.
Methods: We examined 145 DTC patients with indeterminate response to therapy followed up for a median time of 68 months. Tg measurements and neck ultrasound (US) were performed every 6-12 months. The changes over time of repeated measurements of basal Tg were analyzed through the multilevel linear regression.
Results: Seventy (48.3%) out of 145 patients spontaneously achieved an excellent response, while persistent indeterminate response was observed in 62 (42.7%) patients. The remaining 13 (9.0%) patients had progression: 3/13 with biochemical disease and 10/13 with structural disease. Tg steadily increased in patients with progressive disease (mean percentage change + 27.1% at each follow-up visit), while Tg decreased in patients without any evidence of progression (mean percentage change - 8.8%). This different trend between the two groups was not related to either different values of median TSH at baseline (0.32 vs 0.28 mIU/l, respectively) or to different trend of TSH during follow-up (p = 0.76). Basal Tg values did not increase in three out of ten patients with structural disease that was identified by neck US.
Conclusions: The importance of the study is that, in DTC patients with indeterminate response, rising values of unstimulated Tg, independently from the basal levels, may be useful to identify patients with progressive disease. These results are also useful to avoid unnecessary TSH stimulation.
Keywords: Indeterminate response; Ongoing risk; Thyroglobulin; Thyroid cancer; Ultrasensitive assay.
Similar articles
-
[Advances in thyroglobulin assays and their impact on the management of differentiated thyroid cancers].Ann Biol Clin (Paris). 2016 Jan-Feb;74(1):21-7. doi: 10.1684/abc.2015.1106. Ann Biol Clin (Paris). 2016. PMID: 26711165 Review. French.
-
Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.Endocrine. 2016 Jul;53(1):166-73. doi: 10.1007/s12020-015-0842-0. Epub 2016 Jan 18. Endocrine. 2016. PMID: 26782372
-
Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.Endocrine. 2016 Nov;54(2):460-466. doi: 10.1007/s12020-016-0989-3. Epub 2016 May 17. Endocrine. 2016. PMID: 27189148
-
The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.Clin Endocrinol (Oxf). 2003 May;58(5):556-61. doi: 10.1046/j.1365-2265.2003.01744.x. Clin Endocrinol (Oxf). 2003. PMID: 12699436
-
Follow-up of differentiated thyroid carcinoma.Minerva Endocrinol. 2004 Dec;29(4):161-74. Minerva Endocrinol. 2004. PMID: 15765026 Review. English, Italian.
Cited by
-
The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer.Front Endocrinol (Lausanne). 2022 Jun 2;13:872527. doi: 10.3389/fendo.2022.872527. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35721746 Free PMC article. Review.
-
Temporal Evolution and Prognostic Role of Indeterminate Response Sub-Groups in Patients with Differentiated Thyroid Cancer after Initial Therapy with Radioiodine.Cancers (Basel). 2023 Feb 16;15(4):1270. doi: 10.3390/cancers15041270. Cancers (Basel). 2023. PMID: 36831612 Free PMC article.
-
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response.Front Endocrinol (Lausanne). 2023 Apr 20;14:1133958. doi: 10.3389/fendo.2023.1133958. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37152950 Free PMC article. Review.
-
Prognostic role and characteristics of the indeterminate response in differentiated thyroid cancer: a systematic review.Endocrine. 2024 Jun;84(3):812-821. doi: 10.1007/s12020-024-03688-5. Epub 2024 Jan 24. Endocrine. 2024. PMID: 38265607
-
Differentiated Thyroid Cancer with Biochemical Incomplete Response: Clinico-Pathological Characteristics and Long Term Disease Outcomes.Cancers (Basel). 2021 Oct 29;13(21):5422. doi: 10.3390/cancers13215422. Cancers (Basel). 2021. PMID: 34771585 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous